Ramizol®: A new treatment for Clostridium difficile associated disease

A scientific paper released today in the Journal of Antibiotics presents the pre-clinical development of Ramizol(R), a first generation drug belonging to a new class of styrylbenzene antibiotics with a novel mechanism of action. The research was undertaken by Australian company Boulos & Cooper Pharmaceuticals in partnership with the University of South Australia, Flinders University, Eurofins ["]